Conjunctivitis Research - Pink Eye, Symptoms, Causes, Treatment, Medication

Conjunctivitis Research Today is a free monthly online journal that collates and summarizes the latest research about Conjunctivitis, including details on pink eye, symptoms, causes, treatment, medication.


Conjunctivitis Research Today

Home

View Latest Issue

Information About Conjunctivitis

Books on Conjunctivitis

Advertising in Research Today

View Other Research Today Publications



Topical cyclosporine A in severe steroid-dependent childhood phlyctenular keratoconjunctivitis.

Doan S, Gabison E, Gatinel D, Duong MH, Abitbol O, Hoang-Xuan T

Service d'ophtalmologie, Hôpital Bichat, Fondation A. de Rothschild, 46 rue Henri Huchard, 75018 Paris, France. serge.doan@noos.fr

PURPOSE: To assess the efficacy of topical cyclosporine A (CsA) in children with phlyctenular keratoconjunctivitis associated with severe steroid-dependent corneal inflammation. DESIGN: Prospective, noncomparative, interventional case series. METHODS: patients: Children with phlyctenular keratoconjunctivitis associated with severe steroid-dependent corneal inflammation and not responding to oral antibiotics (cyclines or erythromycin). intervention: Topical CsA 2% four times daily, initially combined with topical dexamethasone for the first week. main outcome measures: Efficacy was judged by the patients (symptoms and ocular redness) and by the ophthalmologist (ocular redness and corneal inflammation). The patients were monitored for adverse effects, and cyclosporinemia was determined every 3 months. RESULTS: We studied 11 children (13 eyes) with a mean age of 9 years (range, 4 to 15 years). Inflammation was controlled in all the eyes within 14 days. Inflammation did not recur during CsA monotherapy, during a mean follow-up of 12 +/- 8 months (range, 6 to 31 months). CsA therapy was stopped in eight patients (10 eyes) after a mean treatment duration of 13 +/- 9 months (range, 6 to 31 months), and no recurrences occurred during 10 +/- 3 months of follow-up (range, 6 to 12 months). Local tolerance of CsA was good. None of the patients had detectable CsA blood levels. CsA was withdrawn in one case after 6 months, because of generalized skin rash. CONCLUSIONS: Long-term topical CsA 2% therapy is safe and effective in children with phlyctenular keratoconjunctivitis associated with severe steroid-dependent corneal inflammation.

Published 2 January 2006 in Am J Ophthalmol, 141(1): 62-66.
Full-text of this article is available online (may require subscription).

Place a permanent text-link or advertisement here for just US$15.

© 2004-2008 Conjunctivitis Research Today. All Rights Reserved.



Conjunctivitis Research Today Archive:

Volume 1 (2004)
  Issue 1 (October)
  Issue 2 (November)
  Issue 3 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)



Conjunctivitis Books

Blepharitis and Conjunctivitis. Guidelines for Diagnosis and Treatment

Blepharitis and Conjunctivitis. Guidelines for Diagnosis and Treatment